Clinical Trials Logo

Choroidal Neovascularization clinical trials

View clinical trials related to Choroidal Neovascularization.

Filter by:

NCT ID: NCT00239928 Completed - Clinical trials for Macular Degeneration

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Start date: September 2005
Phase: Phase 2
Study type: Interventional

This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion of the preceding study (A5751010).

NCT ID: NCT00220805 Completed - Clinical trials for Macular Degeneration

Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

Start date: January 2004
Phase: Phase 2
Study type: Interventional

This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult Choroidal Neovascularization (CNV).

NCT ID: NCT00150202 Completed - Clinical trials for Macular Degeneration

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

Start date: July 2004
Phase: Phase 3
Study type: Interventional

This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.

NCT ID: NCT00138632 Completed - Clinical trials for Wet Age-Related Macular Degeneration

Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

ADVANCE
Start date: September 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema. In Cohort 1 verteporfin/PDT is the active control. The protocol was amended to reflect the current standard of care for AMD. As a result, ranibizumab is the active control for Cohort 2.

NCT ID: NCT00135837 Completed - Clinical trials for Age-Related Macular Degeneration

Photodynamic Therapy in Occult-Only Lesions (POOL)

Start date: June 2003
Phase: Phase 4
Study type: Interventional

Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.

NCT ID: NCT00121407 Completed - Clinical trials for Macular Degeneration

Visudyne® in Occult (VIO)

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable safety profile, significantly reduce the risk of vision loss compared with placebo (sham treatment).

NCT ID: NCT00090623 Completed - Clinical trials for Macular Degeneration

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Start date: August 2004
Phase: Phase 3
Study type: Interventional

This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

NCT ID: NCT00058994 Completed - Clinical trials for Macular Degeneration

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

NCT ID: NCT00051129 Completed - Clinical trials for Macular Degeneration

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).

NCT ID: NCT00021736 Completed - Clinical trials for Macular Degeneration

Phase II/III Study of Anti-VEGF in Neovascular AMD

Start date: July 2001
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD